证券代码：000661 证券简称：长春高新 公告编号：2026-012 长春高新技术产业（集团）股份有限公司 关于子公司 GenSci128 片获得美国食品药品监督管理局 孤儿药资格认定的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）子公 司——长春金赛药业有限责任公司（以下简称"金赛药业"）收到美国食品药品 监督管理局（以下简称"FDA"）通知，授予 GenSci128 片孤儿药资格认定（Orphan Drug Designation,ODD），用于胰腺癌的治疗，现将相关情况公告如下： 一、药品的基本情况 产品名称：GenSci128 片 申请事项：FDA 孤儿药认定 申请编号：DRU-2025-11322 申请人：长春金赛药业有限责任公司 适应症：胰腺癌的治疗 二、药品的其它情况 GenSci128 片属治疗用化药 1 类新药，在美国新药注册类别"505b1"，是针 对 TP53 Y220C 突变的选择性重激活剂，拟用于治疗携带 TP53 Y220C 突变的局 部晚期或转移性实体瘤，涵盖 ...

Market Strategy - The three major indices opened lower but rose throughout the day, with the oil and gas sector experiencing significant gains [5][6] - The A-share market showed resilience despite global market adjustments, with a total trading volume reaching 30 trillion yuan [9] Company Tracking - Changchun High-tech (000661.SZ) received acceptance for the clinical trial application of GenSci161 injection, which targets key pro-inflammatory cytokines and aims to provide new treatment options for moderate to severe patients [35] - Dongwu Securities (601555.SH) plans to acquire control of Donghai Securities through the issuance of A-shares, with an agreement signed to purchase 26.68% of the company's shares [37] Industry Dynamics - International oil prices surged, with Brent crude oil rising 13% to over 82 USD per barrel due to geopolitical tensions in the Middle East [25] - The panel industry is experiencing a trend towards larger sizes, with significant growth expected in 65-inch and larger panels, driven by market demand and pricing strategies [33] - The Congolese copper export route has been disrupted due to a bridge collapse, affecting transportation and logistics in the region [31]

获得受理的公告 证券代码：000661 证券简称：长春高新 公告编号：2026-011 长春高新技术产业（集团）股份有限公司 关于子公司 GenSci161 注射液境内生产药品注册临床试验申请 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）控股 子公司——长春金赛药业有限责任公司（以下简称"金赛药业"）收到国家药品 监督管理局核准签发的《受理通知书》，金赛药业 GenSci161 注射液的境内生产 药品注册临床试验申请获得受理，现将有关情况公告如下： 一、药品的基本情况 产品名称：GenSci161 注射液 申请事项：境内生产药品注册临床试验 受理号：CXSL2600282、CXSL2600283 申请人：长春金赛药业有限责任公司 审批结论：经审查，决定予以受理 适应症：用于子宫内膜异位症和化脓性汗腺炎 二、药品的其它情况 GenSci161 注射液是金赛药业自主研发的一款治疗用生物制品 1 类药物，拟 用于治疗子宫内膜异位症和化脓性汗腺炎。 子宫内膜异位症是女性常见慢性系统性炎症性疾病，发病率约 ...

证券日报网讯 2月27日，长春高新在互动平台回答投资者提问时表示，公司目前获批临床的适应症是用 于改善因高促性腺激素性性腺功能减退症、5α-还原酶2缺乏症、雄激素合成减少的先天性肾上腺皮质增 生症、特发性的原因导致的儿童小阴茎，未来如有其他达到披露标准的新情况，公司将按照法律法规要 求履行相应的披露义务。 （文章来源：证券日报） ...

Group 1 - The company, Changchun High-tech (000661), responded to investor inquiries on February 27, indicating that employee information will be disclosed in accordance with legal and regulatory requirements in the relevant sections of periodic reports [1]

证券之星消息，2月27日，生物经济（970038）指数报收于2178.02点，跌0.57%，成交7.9亿元，换手率 0.06%。当日该指数成份股中，上涨的有33家，英科医疗以5.08%的涨幅领涨，下跌的有12家，长春高 新以2.77%的跌幅领跌。 资金流向方面，生物经济（970038）指数成份股当日主力资金净流出合计2.53亿元，游资资金净流出合 计2.08亿元，散户资金净流入合计4.61亿元。成份股资金流向详情见下表： 生物经济（970038）指数十大成份股详情如下： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - Changchun High-tech Industry (Group) Co., Ltd. announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the clinical trial application of GenSci141 ointment, the world's first specific treatment for children's micropenis, marking a historic breakthrough in a long-neglected area of standard drug treatment [2][3]. Company Summary - The approval of GenSci141 ointment represents a shift from empirical medication to precision treatment for children's micropenis, providing the first clinically validated standard treatment option [3]. - The stock price of Changchun High-tech reacted strongly to the news, closing at 97.26 yuan per share on February 25, and reaching a peak of 108 yuan on February 26, with a cumulative increase of over 12% in two days, pushing the total market value beyond 40 billion yuan [2]. - The company maintains a cautious stance regarding the project, indicating that it is still in the early stages and that the drug has only received approval for clinical trials, with no confirmed timeline for market launch [3][4]. Industry Summary - The biopharmaceutical industry is a core component of China's strategic emerging industries, essential for public health, technological innovation, and enhancing the country's self-sufficiency in medicine [4]. - The Chinese biopharmaceutical market is projected to grow from 345.7 billion yuan in 2020 to 524.2 billion yuan by 2024, with expectations to exceed 800 billion yuan by 2028, maintaining an annual growth rate of 10%-12% [4]. - The industry value chain consists of upstream raw materials, midstream research and production, and downstream distribution and consumption, with the midstream segment holding the highest profit margins due to its technological barriers [6][8].

Core Viewpoint - Changchun High-tech's stock price declined over 4% following the announcement of the approval for a pediatric medication, with the company indicating that the drug will take at least three years to reach the market [1] Group 1: Company Developments - Changchun High-tech's subsidiary, GenSci, received approval for clinical trials of GenSci141 ointment, aimed at treating conditions leading to pediatric micropenis [1] - The company stated that the timeline from clinical approval to market launch is typically a minimum of three years, subject to uncertainties in each trial phase [1] Group 2: Market Reaction - Following the announcement, Changchun High-tech's stock opened lower, trading at 95.88 yuan per share at the time of reporting [1] - A representative from the company's securities department commented that the stock price fluctuations do not have any special reasons behind them [1]

Summary of Longcheng Gaoxin (000661.SZ) Conference Call Company Overview - **Company**: Longcheng Gaoxin (000661.SZ) - **Industry**: Pediatric Rare Diseases Core Insights - The market perception of Longcheng Gaoxin remains limited to "growth hormone dependency," overlooking the company's significant investments in the pediatric rare disease sector [1] - GenSci141 ointment, the world's first First-in-class topical medication for pathological micropenis in children, has recently received clinical approval, marking a step closer to commercialization [1] Market Potential and Product Insights - GenSci141 is expected to replicate the commercial success of growth hormones due to its four core elements: "global innovation, rare disease necessity, pediatric channel reuse, and high pricing power" [2] - Estimated total market potential for GenSci141 in China is projected to reach 30-40 billion CNY, with potential doubling to 60-80 billion CNY if successfully launched overseas, which could offset performance pressures from growth hormone procurement [2] Market Space Re-evaluation 1. **Target Population and Penetration Rate**: - The incidence rate for pathological micropenis is 0.03%, ensuring medical seriousness and payment rigidity [3] - Current stock of male children aged 3-12 in China is approximately 36,000, with an annual addition of about 2,100 new cases [3] - Expected penetration rate of 30% by the fifth year post-launch, supported by GenSci's strong pediatric physician education system [3] 2. **Pricing and Revenue Projections**: - High pricing power due to the unique nature of the product with no direct competitors; estimated annual treatment cost is 45,000 CNY [3] - Steady-state revenue is projected to be between 486 million CNY (neutral) and 792 million CNY (optimistic) five years post-launch [3] - Total lifecycle value in China is estimated at approximately 3.42 billion CNY [3] 3. **Performance Elasticity and Channel Reuse**: - The expected steady-state revenue of 486 million CNY would account for about 6.5% of current revenue for Jinsai Pharmaceutical, marking it as the most certain incremental growth after growth hormones [4] - The product will fully utilize existing pediatric channels, ensuring high commercialization efficiency without significant additional sales costs [4] Company Fundamentals - The company has moved past its transformation pains, with positive signals accumulating: 1. Management changes with the return of key technical figure Jin Lei as Group General Manager, shifting strategic focus towards innovative drugs [5] 2. Increased R&D expenditure, reaching 1.733 billion CNY in the first three quarters of 2025, supporting a robust innovation pipeline [5] 3. Significant pipeline progress with the oral small molecule growth hormone secretagogue (GS3-007a) for idiopathic short stature (ISS) also receiving clinical acceptance [6] Profit Forecast and Valuation - Profit forecasts indicate net profits of 2.119 billion CNY, 2.296 billion CNY, and 2.517 billion CNY for 2025-2027 [7] - Current stock price corresponds to a PE ratio of less than 20 for 2026, at historical valuation lows; potential for significant valuation recovery as the value of innovative pipelines is recognized [7] - Target price estimated at over 144.48 CNY based on a 28x PE ratio for 2025 [7] Risk Factors 1. Clinical and approval risks for GenSci141, with uncertainties surrounding Phase III trials and market approval [8] 2. Limitations on expanding indications could restrict market potential if future off-label uses are strictly regulated [8] 3. Ongoing procurement pressures on the core growth hormone business and potential competition from similar mechanism drugs could alter the competitive landscape [8] Conclusion Longcheng Gaoxin is at a critical juncture with its "old business bottoming out and new business breakthroughs." The GenSci141 ointment, with its unique global innovation and pediatric necessity, is poised to be a key driver for the company to navigate through cycles [9][10]

Group 1: Automotive Industry - Stellantis, the global fourth-largest automotive manufacturer, reported a net loss of €22.3 billion (approximately ¥180.2 billion) for the year 2025, primarily due to €25.4 billion in extraordinary restructuring costs incurred in the second half of the year [1] - Despite the losses, Stellantis showed signs of recovery in the second half of 2025, with revenue growth and significantly improved cash flow compared to the first half [1] - The company's net revenue for 2025 was €153.5 billion, a slight decrease of 2% year-on-year, attributed to foreign exchange impacts and declining new car prices in the first half [1] Group 2: Pharmaceutical Industry - Changchun High-tech's subsidiary, JinSai Pharmaceutical, received approval for clinical trials of GenSci141 ointment, a drug aimed at treating male children's developmental disorders, marking a significant market opportunity as no similar products exist globally [3][4] - Following the announcement, Changchun High-tech's stock price surged over 12% within two days, reflecting strong market interest and potential for growth in the pharmaceutical sector [2] Group 3: Technology and Communication - WeChat launched a new feature allowing users to check how many chats a file has been used in, which does not duplicate storage space, addressing user concerns about storage management [6] - Meituan has applied for trademarks related to real estate, indicating a strategic move into property-related services [5] Group 4: Corporate Changes - Ctrip announced the resignation of its co-founder and president, Fan Min, along with board member Ji Qi, as part of a restructuring effort to enhance the board's professional diversity and strategic oversight capabilities [7][8] - ByteDance's valuation has risen to $550 billion, reflecting a 66% increase compared to last year's stock buyback valuation, indicating strong investor confidence in the company's growth potential [9]